Important Links

Login

Polls

Recent Posts

Archive for October, 2008

Aetna Tackles Quality Issues In Genetic Testing For Breast Cancer…

Friday, October 31st, 2008

Main Category: Breast Cancer Also Included In: Genetics Article Date: 31 Oct 2008 - 6:00 PDT Aetna is implementing a comprehensive plan to increase the quality of genetic diagnosis and treatment of breast …

Shape shift rules cancer spread

Friday, October 31st, 2008

UK scientists have worked out how cancer cells change their shape to spread around the body.

Troublesome hot flushes ‘are a sign breast cancer drugs are working’

Friday, October 31st, 2008

Upside: Breast cancer is less likely to come back if women develop side effects to certain drugs, say scientists Breast cancer patients who develop hot flushes usually feel that the symptoms are only adding to …

Identification Of Mechanism, Possible Drug Treatment For Tumors In Neurofibromatosis

Friday, October 31st, 2008

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood. The researchers, who were funded by the National Institutes of Health (NIH) and the Department of Defense (DOD), also found […]

Biothera To Present Imprime PGG(R) Clinical Trial Results At The International Society For Biological Therapy Of Cancer

Friday, October 31st, 2008

Biothera will present the results of two separate Phase I clinical trials evaluating the safety of Imprime PGG®, the company’s developmental immunotherapy cancer drug, at the International Society for Biological Therapy of Cancer on Saturday, November 1 in San Diego, Calif. Biothera has completed two randomized, double-blind, placebo-controlled clinical studies in a total […]

ERBITUX® Supplemental Biologics License Application For First-Line Recurrent Or Metastatic Head And Neck Cancer Accepted For Priority Review By FD

Friday, October 31st, 2008

ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the companies’ supplemental Biologics License Application (sBLA) to broaden the indication for ERBITUX® (cetuximab) to include use in combination with platinum-based chemotherapy for the first-line treatment of patients […]

‘New’ Estrogen Receptor Found To Be Key Player In Tamoxifen Resistance

Friday, October 31st, 2008

Researchers at Georgetown University Medical Center have discovered a novel way in which breast cancer cells become resistant to tamoxifen, the world’s largest-selling breast cancer prevention and treatment drug. They say the findings could provide a way to identify tamoxifen users who are no longer benefiting from the drug, allowing doctors to try another therapy […]

Aetna Tackles Quality Issues In Genetic Testing For Breast Cancer - Promoting Evidence-based Approach

Friday, October 31st, 2008

Aetna (NYSE:AET) is implementing a comprehensive plan to increase the quality of genetic diagnosis and treatment of breast cancer. The company is guiding members and physicians to laboratories that meet national guidelines for genetic testing accuracy. Aetna also is funding research to understand the use of genetic tests in breast cancer treatment.

A Key To Aggressive Breast Cancer Discovered By UC Davis Researchers

Friday, October 31st, 2008

In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth.

Swayze speaks of treatment ‘hell’

Friday, October 31st, 2008

Actor Patrick Swayze says that undergoing chemotherapy to treat pancreatic cancer was "hell on wheels".

Curezone Panell